Evidence map›Paper›PMID 40810209›Full record

ReviewCancer2025

Artificial intelligence across the cancer care continuum.

Irbaz Bin Riaz, Muhammad Ali Khan, Travis J Osterman

Abstract readReview
In one paragraph

Review in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. AI and human expertise in cancer care - striving for synergy.Nature reviews. Clinical oncology · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Irbaz Bin RiazDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Muhammad Ali KhanDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.ORCID https://orcid.org/0009-0002-0079-9935
Travis J OstermanDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-2841-8121

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Oncology Knowledge Rapid Alerts: Integrating biomarker-driven clinical decision support for therapy selection at point-of-careR21CA274545 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MICHEEL, CHRISTINE M, OSTERMAN, TRAVIS J · 2022 to 2022
$450k
Ingram ProfessorshipNCI NIH HHS 1R21CA274545-01NCI NIH HHS P30 CA068485NCI NIH HHS R21 CA274545
6 · The paper itself

Abstract

Artificial intelligence (AI) holds significant potential to enhance various aspects of oncology, spanning the cancer care continuum. This review provides an overview of current and emerging AI applications, from risk assessment and early detection to treatment and supportive care. AI-driven tools are being developed to integrate diverse data sources, including multi-omics and electronic health records, to improve cancer risk stratification and personalize prevention strategies. In screening and diagnosis, AI algorithms show promise in augmenting the accuracy and efficiency of medical image analysis and histopathology interpretation. AI also offers opportunities to refine treatment planning, optimize radiation therapy, and personalize systemic therapy selection. Furthermore, AI is explored for its potential to improve survivorship care by tailoring interventions and to enhance end-of-life care through improved symptom management and prognostic modeling. Beyond care delivery, AI augments clinical workflows, streamlines the dissemination of up-to-date evidence, and captures critical patient-reported outcomes for clinical decision support and outcomes assessment. However, the successful integration of AI into clinical practice requires addressing key challenges, including rigorous validation of algorithms, ensuring data privacy and security, and mitigating potential biases. Effective implementation necessitates interdisciplinary collaboration and comprehensive education for health care professionals. The synergistic interaction between AI and clinical expertise is crucial for realizing the potential of AI to contribute to personalized and effective cancer care. This review highlights the current state of AI in oncology and underscores the importance of responsible development and implementation.

Indexed as

Artificial IntelligenceContinuity of Patient CareNeoplasmsHumansMedical OncologyPrecision MedicineRisk Assessmentartificial intelligence (AI)cancer screeningcancer survivorshipend‐of‐life caremedical oncologyradiation oncologysurgical oncology

Identifiers

PMID40810209
PMCPMC12351523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.